Blastic transformation of BCR-ABL1 positive chronic myeloid leukaemia through acquisition of CBFB-MYH11 and mutant KIT

Khalid Shoumariyeh^{1

2}, Saskia Hussung¹, Christoph Niemöller¹, Sabine Bleul¹, Pia Veratti¹, Marie Follo¹, Julian Riba³, Ulrike Philipp¹, Juliane M Palmer¹, Dietmar Pfeifer¹, Milena Pantic¹, Manja Meggendorfer⁴, Björn Hackanson^{1

5}, Jürgen Finke¹, Torsten Haferlach⁴, Justus Duyster^{1

2

6}, Cornelius Miething^{1

2

6}, Heiko Becker¹, Nikolas von Bubnoff^{1

7}

Affiliations

¹ Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
² German Cancer Consortium (DKTK), Freiburg, Germany.
³ Department of Microsystems Engineering - IMTEK, University of Freiburg, Freiburg, Germany.
⁴ MLL Munich Leukemia Laboratory, Munich, Germany.
⁵ Department of Hematology/Oncology, University Medical Center Augsburg, Augsburg, Germany.
⁶ German Cancer Research Center (DKFZ), Heidelberg, Germany.
⁷ Department of Hematology and Oncology, Medical Center, University of Schleswig-Holstein, Lubeck, Germany.

Case Reports

Khalid Shoumariyeh et al. Br J Haematol. 2020 Sep.

. 2020 Sep;190(6):e339-e343.

doi: 10.1111/bjh.16904. Epub 2020 Jun 24.

¹ Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
² German Cancer Consortium (DKTK), Freiburg, Germany.
³ Department of Microsystems Engineering - IMTEK, University of Freiburg, Freiburg, Germany.
⁴ MLL Munich Leukemia Laboratory, Munich, Germany.
⁵ Department of Hematology/Oncology, University Medical Center Augsburg, Augsburg, Germany.
⁶ German Cancer Research Center (DKFZ), Heidelberg, Germany.
⁷ Department of Hematology and Oncology, Medical Center, University of Schleswig-Holstein, Lubeck, Germany.

No abstract available

Keywords: BCR/ABL; CML; acute leukaemia; chronic leukaemia; haematological malignancies.

References

1. Fabarius A, Leitner A, Hochhaus A, Müller MC, Hanfstein B, Haferlach C, et al. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood. 2011;118:6760-8.
1. Hehlmann R, Voskanyan A, Lauseker M, Pfirrmann M, Kalmanti L, Rinaldetti S, et al. High-risk additional chromosomal abnormalities at low blast counts herald death by CML. Leukemia. 2020.
1. Wang W, Cortes JE, Tang G, Khoury JD, Wang S, Bueso-Ramos CE, et al. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood. 2016;127:2742-50.
1. Merzianu M, Medeiros LJ, Cortes J, Yin C, Lin P, Jones D, et al. inv(16)(p13q22) in chronic myelogenous leukemia in blast phase: a clinicopathologic, cytogenetic, and molecular study of five cases. Am J Clin Pathol. 2005;124:807-14.
1. Duployez N, Marceau-Renaut A, Boissel N, Petit A, Bucci M, Geffroy S, et al. Comprehensive mutational profiling of core binding factor acute myeloid leukemia. Blood. 2016;127:2451-9.